The efficacy of the triple therapy, pertuzumab–trastuzumab–docetaxel, was evaluated in ERBB2-mutated NSCLC in the IFCT-1703 R2D2 study [75]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.